Literature DB >> 2522965

IL-2-activated human killer lymphocytes but not their secreted products mediate increase in albumin flux across cultured endothelial monolayers. Implications for vascular leak syndrome.

N K Damle1, L V Doyle.   

Abstract

When cultured with IL-2, human lymphoid cells acquire the ability to lyse various NK-resistant tumor targets. Due to their anti-tumor cytolytic effect, clinical trials with IL-2 alone or IL-2 + IL-2-activated killer (IAK) lymphocytes have been undertaken. However, infusion of therapeutically effective doses of IL-2 is associated with the development of systemic toxicity characterized by exaggerated endothelial permeability, also known as vascular leak syndrome. The present study was designed to examine the effects of IAK cells and their secreted products on vascular endothelial permeability by using an in vitro endothelial permeability model in which the flux of FITC-albumin across endothelial cell (EC) monolayers was measured. When endothelial monolayers were exposed to IAK cells for 2 h, significant increases in the transendothelial permeability to albumin were observed. Exposure of EC to lymphocytes cultured in the absence of IL-2 did not induce significant alteration in the endothelial permeability. In addition, neither culture supernatants of IAK cells nor purified recombinant cytokines, including IL-1 beta, IL-2, IL-3, IL-4, IL-6, TNF-alpha, GM-CSF, M-CSF, and IFN-gamma, had any effect on endothelial permeability in this model. Prior activation of EC with TNF-alpha did not alter the increased permeability induced by IAK cells or lack of it by nonactivated lymphocytes. Dexamethasone treatment of IAK cells abolished their anti-tumor cytolytic effect but only partially inhibited their ability to induce increased endothelial permeability. Pretreatment of IAK cells with mAb directed at the CD11a/CD18 (LFA-1) adhesion complex, and that of EC with mAb directed at the ICAM-1 molecule, inhibited the IAK cell-induced increase in endothelial permeability. These results demonstrate that direct cell-to-cell contact between IAK cells and EC is necessary and sufficient to cause increased endothelial permeability in this model system, and may therefore be an important factor contributing to the development of the vascular leak syndrome observed clinically.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2522965

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

1.  Potentiated lymphokine-activated killer cell activity generated by low-dose interleukin-2 and mismatched double-stranded RNA.

Authors:  H R Hubbell; G D Gibson; R D Bigler
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

2.  Pentoxifylline inhibits interleukin-2-induced toxicity in C57BL/6 mice but preserves antitumor efficacy.

Authors:  M J Edwards; B T Heniford; E A Klar; K W Doak; F N Miller
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

Review 3.  Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. A review of pre-clinical and clinical investigations.

Authors:  R E Merchant; M D Ellison; H F Young
Journal:  J Neurooncol       Date:  1990-04       Impact factor: 4.130

Review 4.  Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association.

Authors:  Umberto Campia; Javid J Moslehi; Laleh Amiri-Kordestani; Ana Barac; Joshua A Beckman; David D Chism; Paul Cohen; John D Groarke; Joerg Herrmann; Carolyn M Reilly; Neal L Weintraub
Journal:  Circulation       Date:  2019-03-26       Impact factor: 29.690

5.  Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a phase I clinical study: induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity.

Authors:  C Scheid; R Young; R McDermott; L Fitzsimmons; J H Scarffe; P L Stern
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

6.  Interleukin-2 induces early multisystem organ edema mediated by neutrophils.

Authors:  R Welbourn; G Goldman; L Kobzik; I Paterson; D Shepro; H B Hechtman
Journal:  Ann Surg       Date:  1991-08       Impact factor: 12.969

7.  In vivo relationship of interleukin-2 and soluble IL-2 receptor to blood-brain barrier impairment in patients with active multiple sclerosis.

Authors:  M K Sharief; R Hentges; M Ciardi; E J Thompson
Journal:  J Neurol       Date:  1993-01       Impact factor: 4.849

8.  Platelet activating factor mediates interleukin-2-induced lung injury in the rat.

Authors:  R Rabinovici; M D Sofronski; J F Renz; L M Hillegas; K M Esser; J Vernick; G Feuerstein
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

9.  Immunomodulation in patients receiving intravenous Bryostatin 1 in a phase I clinical study: comparison with effects of Bryostatin 1 on lymphocyte function in vitro.

Authors:  C Scheid; J Prendiville; G Jayson; D Crowther; B Fox; G R Pettit; P L Stern
Journal:  Cancer Immunol Immunother       Date:  1994-10       Impact factor: 6.968

10.  Capillary leak syndrome associated with elevated IL-2 serum levels after allogeneic bone marrow transplantation.

Authors:  I Funke; O Prümmer; H Schrezenmeier; D Hardt; M Weiss; F Porzsolt; R Arnold; H Heimpel
Journal:  Ann Hematol       Date:  1994-01       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.